000153852 001__ 153852
000153852 005__ 20240229123050.0
000153852 0247_ $$2doi$$a10.1002/gps.5282
000153852 0247_ $$2pmid$$apmid:32100308
000153852 0247_ $$2ISSN$$a0885-6230
000153852 0247_ $$2ISSN$$a1099-1166
000153852 0247_ $$2altmetric$$aaltmetric:76706253
000153852 037__ $$aDKFZ-2020-00470
000153852 041__ $$aeng
000153852 082__ $$a610
000153852 1001_ $$0P:(DE-He78)6cc3cc35505b446fde081e7cd89a4b87$$aMöllers, Tobias$$b0$$eFirst author
000153852 245__ $$aNew use of psychotropic medication after hospitalization among people with dementia.
000153852 260__ $$aChichester [u.a.]$$bWiley$$c2020
000153852 3367_ $$2DRIVER$$aarticle
000153852 3367_ $$2DataCite$$aOutput Types/Journal article
000153852 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1636705172_5414
000153852 3367_ $$2BibTeX$$aARTICLE
000153852 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000153852 3367_ $$00$$2EndNote$$aJournal Article
000153852 500__ $$a2020 Jun;35(6):640-649#EA:C070#LA:C070#
000153852 520__ $$aPsychotropic medication is commonly used among people with dementia (PWD), but it shows modest efficacy and it has been associated with severe adverse events. Hospitalizations are an opportunity for medication management as well as treatment recommendations for outpatient physicians. The aim of this study was to asses factors associated with new use of psychotropic medication after hospitalization among PWD.We conducted a retrospective dynamic cohort study from 2004 to 2015 using claims data from a German health insurance company. PWD were identified by an algorithm that included ICD-10 diagnosis and diagnostic measures. The medication classes included were antidepressants, antipsychotics, anxiolytics or hypnotics/sedatives, and Alzheimer‧s medication. The assessment period was up to 30 days after discharge from the hospital across four hospitalizations.The main predictors for new use of psychotropic medication were similar across medication classes. Neuropsychiatric symptoms (NPS) and the need of care were associated with higher odds of new use of antidepressants, antipsychotics, and anxiolytics or hypnotics/sedatives. A hospital stay due to dementia was an independent predictor for new use across medication classes as well. Delirium increased the odds for new use of antipsychotics and anxiolytics or hypnotics/sedatives.Factors associated with new use of psychotropic medication included delirium, NPS, and the need of care in PWD. The findings highlight the need for preventive interventions and non-medical treatment options in regards to delirium and NPS as well as for a more intensive use of screening tools for inappropriate medication use among PWD. This article is protected by copyright. All rights reserved.
000153852 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000153852 588__ $$aDataset connected to CrossRef, PubMed,
000153852 7001_ $$0P:(DE-He78)d9d72431035d8535d1b65ce9a01c2f60$$aPerna, Laura$$b1$$udkfz
000153852 7001_ $$0P:(DE-HGF)0$$aStocker, Hannah$$b2
000153852 7001_ $$aIhle, Peter$$b3
000153852 7001_ $$aSchubert, Ingrid$$b4
000153852 7001_ $$0P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aSchöttker, Ben$$b5
000153852 7001_ $$aFrölich, Lutz$$b6
000153852 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b7$$eLast author
000153852 773__ $$0PERI:(DE-600)1500455-7$$a10.1002/gps.5282$$gp. gps.5282$$n6$$p640-649$$tInternational journal of geriatric psychiatry$$v35$$x1099-1166$$y2020
000153852 909CO $$ooai:inrepo02.dkfz.de:153852$$pVDB
000153852 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6cc3cc35505b446fde081e7cd89a4b87$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000153852 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d9d72431035d8535d1b65ce9a01c2f60$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000153852 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000153852 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000153852 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000153852 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000153852 9141_ $$y2020
000153852 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000153852 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000153852 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000153852 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000153852 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J GERIATR PSYCH : 2017
000153852 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000153852 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000153852 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000153852 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000153852 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000153852 915__ $$0StatID:(DE-HGF)0130$$2StatID$$aDBCoverage$$bSocial Sciences Citation Index
000153852 915__ $$0StatID:(DE-HGF)1180$$2StatID$$aDBCoverage$$bCurrent Contents - Social and Behavioral Sciences
000153852 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000153852 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000153852 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000153852 9202_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000153852 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000153852 9200_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000153852 980__ $$ajournal
000153852 980__ $$aVDB
000153852 980__ $$aI:(DE-He78)C070-20160331
000153852 980__ $$aUNRESTRICTED